Segall Bryant & Hamill LLC Grows Stake in Zoetis Inc. (NYSE:ZTS)

Segall Bryant & Hamill LLC boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 3.6% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 73,528 shares of the company’s stock after acquiring an additional 2,575 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Zoetis were worth $14,366,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Asset Dedication LLC boosted its stake in shares of Zoetis by 4.8% during the 2nd quarter. Asset Dedication LLC now owns 1,174 shares of the company’s stock worth $204,000 after acquiring an additional 54 shares during the last quarter. Forza Wealth Management LLC raised its holdings in Zoetis by 1.8% in the 2nd quarter. Forza Wealth Management LLC now owns 3,313 shares of the company’s stock worth $574,000 after purchasing an additional 58 shares during the period. Cherry Creek Investment Advisors Inc. lifted its position in Zoetis by 2.0% during the third quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock valued at $590,000 after purchasing an additional 58 shares in the last quarter. L. Roy Papp & Associates LLP grew its holdings in Zoetis by 2.8% during the second quarter. L. Roy Papp & Associates LLP now owns 2,221 shares of the company’s stock valued at $385,000 after purchasing an additional 60 shares during the period. Finally, Grove Bank & Trust increased its position in Zoetis by 0.5% in the third quarter. Grove Bank & Trust now owns 11,763 shares of the company’s stock worth $2,298,000 after buying an additional 61 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $175.67 on Thursday. The firm has a fifty day simple moving average of $186.18 and a two-hundred day simple moving average of $180.47. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The stock has a market capitalization of $79.26 billion, a P/E ratio of 33.02, a PEG ratio of 2.69 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.46 by $0.12. The company had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Zoetis’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.36 earnings per share. On average, analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be paid a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 0.98%. The ex-dividend date is Thursday, October 31st. Zoetis’s payout ratio is currently 32.52%.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on ZTS shares. BTIG Research lifted their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. JPMorgan Chase & Co. lifted their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Piper Sandler lifted their target price on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Finally, Stifel Nicolaus upped their target price on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.